Pfizer has announced its plans to invest US$500 million to construct a state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.
The expansion is meant to help advance Pfizer's gene therapy line, specifically in manufacturing custom-made recombinant adeno-associated virus (rAAV) vectors.
The Sanford plant manufactures therapies used for the late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies.
The Sanford plant will also make components for some of the vaccines, such as Prevnar 13.
This new facility will also provide gene therapies to support both clinical development and eventual commercial development.
|Sanford, North Carolina